S095032-211 Vorasidenib in combination with temozolomide (TMZ) in IDH-mutant glioma

• Research type

  Research Study

• Full title

  A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma

• IRAS ID

  1010845

• Contact name

  Sue Russell

• Contact email

  sue.russell@servier.com

• Sponsor organisation

  Institut de Recherches Internationales Servier (I.R.I.S.)

• Clinicaltrials.gov Identifier

  NCT06478212

• Research summary

  The aim of the study is to evaluate the safety and effectiveness of a combination of vorasidenib (S095032/AG-881) with temozolomide (TMZ) for the treatment of a type of brain cancer. This new experimental combination will be used to treat people with isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutated glioma. The Sponsor of this study is the Institut de Recherches Internationales Servier (I.R.I.S.)

• REC name

  North East - Newcastle & North Tyneside 1 Research Ethics Committee

• REC reference

  24/NE/0200

• Date of REC Opinion

  17 Dec 2024

• REC opinion

  Further Information Favourable Opinion